218 results on '"Rautenberg, Christina"'
Search Results
2. Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis
3. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation
4. Allogene Stammzelltransplantation bei akuten Leukämien
5. Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center
6. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation
7. Supplementary Tables 1 from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
8. Data from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
9. Supplementary Figure 1 from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
10. Wilm’s Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation
11. Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia
12. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis
13. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
14. Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation
15. Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation
16. Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies
17. Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
18. Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS
19. Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia – a single center experience –
20. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
21. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation
22. Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia
23. Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component
24. Allogene Stammzelltransplantation bei akuten Leukämien
25. TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis
26. Venetoclax and Hypomethylating Agents Followed By Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia
27. High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis
28. Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience.
29. sj-docx-1-tah-10.1177_20406207221090882 – Supplemental material for Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors
30. Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors
31. Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)
32. Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia
33. Myelodysplastische Syndrome
34. Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
35. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents : A retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
36. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
37. Role of Splenic Irradiation Prior to Transplant for Myelofibrosis: A Global Collaboration
38. How Much Have Post-Transplant Outcomes Improved Since 2000 for Older Patients with Acute Myeloid Leukemia? a Study from the EBMT Acute Leukemia Working Party
39. ATG/ATLG Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation
40. Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1‐mRNA expression in patients with AML and MDS
41. Acute myeloid leukemia-induced functional inhibition of healthy CD34+ hematopoietic stem and progenitor cells
42. Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia
43. Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia
44. Myelodysplastische Syndrome
45. Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia
46. Wilm’s Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation
47. Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
48. Improving the accuracy of prognostication in chronic myelomonocytic leukemia
49. Impact of Mutation Profile in Chronic Myelomonocytic Leukemia undergoing Allogeneic Hematopoietic Cell Transplantation
50. Monitoring of peripheral blood Wilms’ Tumor 1 (WT1) - mRNA expression as a marker for minimal residual disease after allogeneic stem cell transplantation in patients with myeloid neoplasms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.